Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 5, 2008, Pages 313-317

  Shimomura, Masahiro ^a   Masuda, Satohiro ^a   Goto, Maki ^a   Katsura, Toshiya ^a   Kiuchi, Tetsuya ^b   Ogura, Yasuhiro ^b   Oike, Fumitaka ^b   Takada, Yasutsugu ^b   Uemoto, Shinji ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

FK506; Metabolism; Pharmacokinetics; Prograf

Indexed keywords

AZATHIOPRINE; CYTOCHROME P450 3A5; DRUG METABOLITE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; M II COMPOUND; M-II COMPOUND; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BILIARY TRACT DRAINAGE; CASE REPORT; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; FEMALE; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PHARMACODYNAMICS; POSTOPERATIVE INFLAMMATION; BILE; BLOOD; GENETICS; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

BILE; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS; THIAZOLIDINEDIONES;

EID: 58149279521     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.313     Document Type: Article

References (15)

1. Kiuchi, T., Inomata, Y., Uemoto, S., Asonuma, K., Egawa, H., Hayashi, M., Fujita, S. and Tanaka, K.: Living-donor liver transplantation in Kyoto, 1997. Clin. Transpl., 18: 191-198 (1997).
2. Jain, A., Reyes, J., Kashyap, R., Rohal, S., Abu-Elmagd, K., Starzl, T. and Fung, J.: What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann. Surg., 230: 441-449 (1999).
3. Shiraga, T., Matsuda, H., Nagase, K., Iwasaki, K., Noda, K., Yamazaki, H., Shimada, T. and Funae, Y.: Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol., 47: 727-735 (1994).
4. Gonschior, A. K., Christians, U., Braun, F.,Winkler, M., Linck, A., Baumann, J. and Sewing, K. F.: Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). Br. J. Clin. Pharmacol., 38: 567-571 (1994).
5. Iwasaki, K.: Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab. Pharmacokinet., 22: 328-335 (2007).
6. Yasuhara, M., Hashida, T., Toraguchi, M., Hashimoto, Y., Kimura, M., Inui, K., Hori, R., Inomata, Y., Tanaka, K. and Yamaoka, Y.: Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant. Proc., 27: 1108-1110 (1995).
7. Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G. and Starzl, T.: Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet., 29: 404-430 (1995).
8. Masuda, S. and Inui, K.: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol. Ther., 112: 184-198 (2006).
9. Fukudo, M., Yano, I., Masuda, S., Fukatsu, S., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Tanaka, K. and Inui, K.: Pharmacodynamic analysis of tacrolimus and cyclosporine in patients of living donor liver transplantation. Clin. Pharmacol. Ther., 78: 168-181 (2005).
10. Goto, M., Masuda, S., Saito, H., Uemoto, S., Kiuchi, T., Tanaka, K. and Inui, K.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics, 12: 451-457 (2002).
11. Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda, M., Tanaka, K. and Inui, K.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics, 14: 471-478 (2004).
12. Uesugi, M., Masuda, S., Katsura, T., Oike, F., Takada, Y. and Inui, K.: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics, 16: 119-127 (2006).
13. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S. and Schuetz, E.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27: 383-391 (2001).
14. Lee, S. J., Usmani, K. A., Chanas, B., Ghanayem, B., Xi, T., Hodgson, E., Mohrenweiser, H.W. and Goldstein, J. A.: Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics, 13: 461-472 (2003).
15. Kamdem, L. K., Streit, F., Zanger, U. M., Brockmoller, J., Oellerich, M., Armstrong, V. W. and Wojnowski, J.: Contribution of CYP3A5 to the in vitro Hepatic Clearance of Tacrolimus. Clin. Chem., 51: 1374-1381 (2005).